Mankind Pharma Limited has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a consolidated annual revenue of ₹14,277.64 crore and a profit after tax of ₹1,938.10 crore. Additionally, the Board approved an additional investment of up to ₹500 crore in its wholly-owned subsidiary, Mankind Medicare Private Limited, to drive capacity expansion and support future business growth.
Annual Financial Performance Highlights
For the financial year 2025-26, Mankind Pharma demonstrated robust growth, achieving a consolidated revenue of ₹14,277.64 crore, compared to ₹12,207.44 crore in the previous fiscal year. The consolidated profit after tax for the year ended March 31, 2026, stood at ₹1,938.10 crore. On a standalone basis, the company reported an annual revenue of ₹10,421.18 crore and a profit of ₹2,037.56 crore.
Strategic Investment in Subsidiary
To support long-term growth and infrastructure development, the Board has approved an additional investment of up to ₹500 crore in its wholly-owned subsidiary, Mankind Medicare Private Limited. This investment will be executed in one or more tranches and is primarily designated for capacity expansion and the establishment of new manufacturing facilities, reinforcing the company’s commitment to scaling its healthcare operations.
Leadership and Governance Updates
The company announced several key administrative updates. Mr. Satish Kumar Sharma has been re-appointed as a Whole-Time Director for a new 5-year term starting September 23, 2026. Simultaneously, the company noted the resignation of Mr. Pramod Gokhale, the Global Chief Information Officer, effective May 31, 2026. Furthermore, the Executive Directors, including Mr. Ramesh Juneja, Mr. Rajeev Juneja, and Mr. Sheetal Arora, have voluntarily decided not to draw their commission for the 2025-26 financial year to strengthen the company’s cash position for future business expansions.
Source: BSE
